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Articular cartilage is a smooth, white connective tissue that covers and protects
the ends of long bones to allow for a smooth, frictionless surface on which to glide for
easy movement. Once the tissue is damaged, articular cartilage lacks a direct blood
supply, which results in a limited ability to repair itself. This study explores the effect of
the growth factor BMP-13 on the chondroinduction of primary human bone marrowderived mesenchymal stem cells.
The results demonstrate the limited ability of BMP-13 to exert a strong
chondroinductive effect on human bone marrow-derived MSCs. However, the results do
indicate that BMP-13 has the ability to sustain chondroinduction to a certain extent for up
to 18 days following initiation by 3 days of exposure to TGF-β3. Results are encouraging
for future work that involves growth factor influence on MSCs in articular cartilage tissue
engineering.
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CHAPTER I
INTRODUCTION

Prevalence
Joint and articular cartilage injuries account for over 6 million hospital visits in
the United States each year [1]. Wear and tear on articular cartilage can lead to a loss in
the tissue, further exposing the ends of long bones and leaving them without protection.
Further tissue degradation leads to the most common type of arthritis, osteoarthritis.
Osteoarthritis, or degenerative joint disease, affects an estimated 27 million adults in the
United States [2].
Unlike other tissues, articular cartilage has a low regenerative capacity and once
injured finds it much more difficult to self-repair. The composition and structure of
articular cartilage give rise to the tissue’s unique properties. Due to the complexity of
articular cartilage composition, it has become challenging to restore full function to
damaged or diseased tissue. Currently, there are many different methods employed for
treating articular cartilage lesions; however, many shortcomings exist with these
therapies.
Tissue engineering may provide alternative solutions for articular cartilage repair
and regeneration by developing tissue substitutes that mimic the composition of articular
cartilage. The objective of this research is to determine the precise nature and magnitude
1

of growth factors that regulate chondrogenic mesenchymal stem cell (MSC)
differentiation. In order to make progress towards introducing a tissue-engineered
technique, a basic understanding of articular cartilage structure, composition and function
must first be established.

Articular Cartilage
Articular cartilage is a smooth, white connective tissue that covers and protects
the ends of long bones to allow for a smooth, frictionless surface on which to glide for
easy movement. Serving as shock absorber, articular cartilage assists in distributing the
load of pressure and weight over the entire surface of a joint. When cartilage is damaged,
the smooth gliding motion that bones were once able to achieve is disrupted, and
movement becomes painful. If a joint experiences improper alignment, excessive weight,
overuse, or injury, cartilage wears away. Once damaged, cartilage lacks a direct blood
supply, resulting in a limited ability of the tissue to repair itself. If damaged cartilage is
left untreated, disease can spread throughout the entirety of the tissue causing
degradation, followed by pain, limited ability of joint movement, and possibly the
contraction of osteoarthritis. Orthopedic researchers are continuing to search for new
ways to treat damaged cartilage. Currently, there have been many advances in the
surgical treatment of articular cartilage defects. However, newer techniques involving
tissue-engineered cartilage hold some promise, but their effectiveness and long-term
outcomes have not been currently established.
The knee is a hinge joint that is formed by two bones and held in place by several
different ligaments. As seen in Figure 1.1, the ends of both bones are covered in articular
2

cartilage. The synovial membrane surrounds and protects the knee joint, and also
functions to produce synovial fluid. Synovial fluid acts as a lubricant for our joints and is
responsible for providing cartilage with its slippery surface. The small amount of fluid
that the synovial membrane provides allows forces on joints to not be directly applied to
bones. Cartilage receives nutrients and oxygen, and removes carbon dioxide and waste
from cells within surrounding cartilage by diffusion through the synovial fluid. When the
joint is loaded, fluid carrying waste and carbon dioxide is forced out of cartilage. Once
relieved, the fluid is allowed to diffuse back into the tissue, carrying oxygen and nutrients
with it.

Figure 1.1 Illustration depicting the structure of the knee joint. From (factmonster.com)
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Articular Cartilage Injury
Cartilage injuries and damage can occur from trauma, disease, or repetitive
loading to the joint, and in turn, articular cartilage tissue will lose partial or complete
function. Without a direct blood supply, cartilage is incapable of initiating the healing
process. Articular cartilage trauma injuries can occur either as a chondral fracture or an
osteochondral fracture. Chondral fractures occur when there is trauma to the joint surface
usually in the form of a tear, but which does not affect the underlying subchondral bone.
Osteochondral fractures occur when there is trauma to the joint surface that affects the
underlying subchondral bone. If left untreated, these joint surface fractures can become
progressively worse causing degradation of articular cartilage tissue and possibly the
contraction of osteoarthritis [3]. Osteoarthritis, or degenerative joint disease, is a joint
disease caused by cartilage degeneration and loss in a joint, and those who suffer from
the disease experience pain and stiffness [4].

Composition
Articular cartilage is composed of cells known as chondrocytes and is surrounded
by a complex extracellular matrix (ECM) (Figure 1.2). Chondrocytes account for only
1% of the volume of articular cartilage, and the ECM accounts for the remaining 99%.
Water makes up as much as 80% of articular cartilage tissue weight. The remaining solid
fraction of the tissue is composed of structural macromolecules. Collagen, proteoglycans,
and noncollagenous proteins are the structural macromolecules present in articular
cartilage ECM, and contribute 20% to 40% of the tissue weight.

4

Only one type of cell, the chondrocyte, is present in articular cartilage.
Chondrocytes are formed by a chondroblast, which originates from a MSC. Chondrocytes
are highly specialized cells responsible for producing and maintaining the ECM. These
cells are sparsely distributed and embedded throughout the ECM. Chondrocytes play an
essential role in maintaining the tissue by synthesizing all matrix components. As the
cells secrete matrix material, chondrocytes become confined into small chambers called
lacunae. The lacunae separate chondrocytes from one another, preventing interaction
between cells in the ECM. Because articular cartilage is avascular, chondrocytes receive
nutrients and oxygen through diffusion from the synovial fluid into the cartilage matrix.
The articular cartilage ECM consists of tissue fluid and the framework of
structural macromolecules. The interaction between the tissue fluid and the structural
macromolecules provides articular cartilage with its stiffness and resilience [5, 6]. Water
contributes to the majority of the wet weight of articular cartilage tissue fluid. Articular
cartilage tissue fluid also includes gases, small proteins, metabolites, and high
concentrations of cations. Some water is capable of moving freely in and out of the
tissue. However, the volume, concentration, and behavior of water at a particular time in
the tissue depend primarily upon the interaction with the structural macromolecules [7].

5

Figure 1.2 Illustration depicting the composition of articular cartilage. From (bidmc.org)

There are three classes of structural macromolecules present in articular cartilage,
collagen, proteoglycans and non-collagenous proteins. These structural macromolecules
exist throughout articular cartilage in varying concentrations and contributions to the
tissue. Of the total 20% to 40% contributed wet weight, structural macromolecules
account for the following, collagen (10%), proteoglycans (10%), and noncollagenous
proteins (5% - 10%).
Collagen configuration can be described as a fibrous protein composed of three
chains of amino acids that take that shape of triple helix. Making up approximately 60%
of the dry weight of cartilage; collagen functions to create a framework housing the other
components of cartilage. Type II collagen is the most abundant collagen found in
6

articular cartilage, and accounts for 90% - 95% of the collagen content present in the
tissue. Type II collagen fibers cross-link to create the major support network for the
ECM, giving articular cartilage its tensile strength. Collagen types III, VI, IX, X, XI, XII,
and XIV are also present in articular cartilage tissue in smaller amounts.
Proteoglycans can be described as macromolecules composed of a central core
protein with highly fixed negatively charged glycosaminoglycan (GAG) subunits
attached to form a bottlebrush-like structure. The two main types of GAG found in
articular cartilage are chondroitin sulfate and keratin sulfate. Proteoglycans can exist as
individual monomers or also bind to a hyaluronic acid backbone by link proteins to form
a macromolecule, the aggrecan. The aggregating proteoglycans function to help maintain
the fluid within the ECM and the concentration of electrolytes in the tissue fluid [7]. Due
to their highly negative charge, GAG molecules are extremely hydrophilic and can trap
large amounts of water within the ECM, providing articular cartilage with its definitive
elastic behavior. The large size of the aggrecan function to trap proteoglycans within the
network of collagen, and in turn provides articular cartilage tissue with its stiffness.
Figure 1.3 illustrates the structure of the proteoglycan macromolecule.
Non-collagenous proteins and glycoproteins contribute 15% to 20% of the dry
weight of articular cartilage. For the purposes of this study, we will concentrate on only
one of these non-collagenous proteins, cartilage oligomeric matrix protein (COMP).
COMP is an acidic protein and is concentrated within the territorial matrix of the
chondrocyte. COMP appears to be present only within cartilage, and has the capacity to
bind to chondrocytes [8, 9]. Previous studies support the belief that COMP plays a role in
cell growth and division and the self-destruction of cells, as well as in the regulation of
7

cell movement and attachment [10, 11]. However, the precise function of COMP remains
unknown.

Figure 1.3 Illustration depicting the components of the ECM of articular cartilage. From
(arthritis-research.com)
Tissue Engineering
The engineering of living tissue, tissue engineering, can be defined as the use of
living cells, manipulated through their extracellular environment to develop biological
substitutes for implantation into the body and/or to foster the remodeling of existing
tissue [12]. The purpose of tissue engineering is to repair, replace, enhance, or maintain
the function of a particular tissue or organ. Current surgical therapies in articular cartilage
repair have yielded unsatisfactory and short-term results in the method of healing
cartilage tissue. Tissue engineering is a fast-growing area of research that may serve as an
8

alternative approach for providing articular cartilage tissue repair or replacement without
the negative shortcomings associated with current therapies. Advancements in science
have brought tissue engineering to the forefront of the scientific research community.
However, due to its complex composition and unique properties, cartilage is considered
one of the most difficult tissues to recreate.

Cell Source
MSCs are unspecialized, undifferentiated cells that are characterized by their
ability for long-term self-renewal and potential to produce different cell types in
differentiation. Ernest A. McCulloch and James E. Till first identified bone marrow
derived MSCs in the 1960s as being a clonal source of cells [13]. MSCs are capable of
dividing and replicating themselves over long periods of time through a process called
proliferation.
Additional work, in the 1970s and 1980s, conducted by Friedenstein, et al.,
expanded upon the potential of MSCs by demonstrating their capacity for multilineage
differentiation [14, 15]. MSCs lack any tissue-specific structures that allow the cell to
perform specialized functions. Through a process called differentiation MSCs can give
rise to tissue specific cells. MSCs have proven to demonstrate the capability to
differentiate into cells of multiple lineages, including chondrocyte, osteoblast, myoblast,
adipocyte, and fibroblast [16-23]. Figure 1.4 illustrates the mechanism by which MSCs
undergo proliferation and differentiation. These characteristics have made MSCs a
popular cell source among current experimental approaches to articular cartilage tissue
engineering. However, such approaches rely on efficient lineage-specific differentiation
9

of MSCs to a desired mature cell, which frequently involves addition of a transforming
growth factor to the culture medium.
Chondrogenesis is the term used to describe the process by which a stem cell is
differentiated into a mature chondrocyte. However, MSCs can only undergo
chondrogenic differentiation when induced by various intrinsic and extrinsic factors.
Growth factors represent a group of biologically active polypeptides produced by the
body, which can stimulate cell proliferation and differentiation to a particular phenotype.
In articular cartilage, growth factors control homeostasis and development [24]. Both
MSCs and growth factors are promising tools in the ever-evolving field of cartilage tissue
engineering. However, determining the growth factor, growth factor concentration, and
growth factor combination to apply to MSCs in order to achieve a cartilage-like tissue has
proved challenging.

10

Figure 1.4 Illustration depicting the cellular proliferation and chondrogenic
differentiation mechanism of MSCs. From [25].
Growth Factors
Numerous studies have reported efficient chondroinduction of MSCs using either
transforming growth factor beta-1 (TGF-β1) [26-29] or TGF-β3 [30-36]. For example,
adult stem cells from bone marrow cultured in defined medium containing 10 ng/ml
TGF-β1 steadily increased mRNA expression of COMP, aggrecan, and type II collagen
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over a 14-day period [34]. In a head-to-head comparison, TGF-β3 was found to stimulate
expression of cartilage ECM components to a greater extent than TGF-β1 [30].
A potential drawback of the use of TGF-β3 for chondroinduction is that it may
stimulate continued differentiation towards a hypertrophic phenotype as evidenced by
increasing type X collagen expression [30]. By contrast, bone morphogenetic protein-13
(BMP-13) has been shown to support chondrogenesis in C3H10T1/2 cell cultures, but not
terminal differentiation to hypertrophic chondrocytes [37]. A separate study using
articular chondrocytes confirmed that BMP-13 does not promote hypertrophy [38]. The
presence of type X collagen, only near the cells of the calcified cartilage zone of articular
cartilage and the hypertrophic zone of growth plate, suggests that it has a role in cartilage
mineralization.
BMP-13 was first identified and isolated as a component of bovine cartilage [39].
BMP-13, also known as cartilage-derived morphogenetic proteins-2 (CDMP-2), and the
human homolog of mouse Gdf-6, belong to the TGF-β superfamily. Members of the
superfamily are essential for the formation of cartilaginous tissue during early limb
development [39, 40]. Previous reports (38, 41-44) have demonstrated the effects of
BMP-13 in osteochondrogenesis using recombinant or adenovirus-mediated human
BMP-13 (hBMP-13), and have also demonstrated that BMP-13 promoted chondrogenic
differentiation in a variety of cells [41] and positively regulated growth and maintenance
of articular cartilage [42]. However, two studies have reported that BMP-13 induced
neotendon/ neoligament formation in vivo [45, 46]. The biological effects of BMP-13
remain controversial, and no studies have examined the effects of overexpression of
hBMP-13 in cell culture models on primary human bone marrow MSCs.
12

The purpose of the current study was to determine the potential for BMP-13 to
initiate and maintain chondroinduction of primary human bone marrow MSCs.
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CHAPTER II
EXPERIMENTAL METHODS

Experimental Design
In order to determine the effect of growth factor BMP-13 on chondrogenesis of
human bone marrow-derived MSCs, a pellet culture experiment was designed in order to
compare the effects of growth factors, TGF-β3 and BMP-13. Four experimental groups
were formed: a control group, a group supplemented with TGF-β3, a group supplemented
with BMP-13 and a group supplemented with both TGF-β3 and BMP-13. The experiment
was conducted over a 21-day period. The pattern of expression of key ECM components,
as well as components known to stimulate a hypertrophic phenotype, were studied in
order to develop a better understanding of the steps in the pathway leading from
undifferentiated stem cell to mature chondrocyte.

Cell Source
Human multipotential marrow stromal cells (21 year-old female) frozen at
passage 1 were provided by the Texas A&M Health Science Center College of Medicine
Institute for Regenerative Medicine. These cells were extensively characterized and
confirmed to meet the minimal criteria which define human MSCs as established by the
Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular
14

Therapy [47]. These criteria include expression of the CD105, CD73 and CD90 surface
molecules and display of multilineage differentiation in vitro.
Cells were thawed into expansion medium (Dulbecco’s modified Eagle Medium
(DMEM) containing 10% fetal bovine serum (FBS) and 1% antibiotic antimycotic
solution) and plated at approximately 5×103 cell/cm2 in two T-175 flasks. Cultures were
maintained at 37°C in a humidified environment containing 95% air and 5% CO2, and the
cells were subcultured prior to reaching confluence. When passage 3 cells approached
confluence, they were detached using trypsin, which was then neutralized by the addition
of 10% FBS. RNA was isolated from five independent samples of these monolayer
expanded cells to serve as a baseline for calculating subsequent changes in gene
expression. These cells will be referred to as undifferentiated MSCs.

Pellet Culture
After centrifugation and aspiration of trypsin, cells were resuspended in differing
media from which one control and three experimental groups were formed. Control group
cells were resuspended in expansion medium. The three experimental groups were BMP13, TGF-β3, and (TGF-β3→BMP-13). Cells in the BMP-13 group were resuspended in
defined chondrogenic medium (DCM) containing 10 ng/ml BMP-13, and those in the
remaining two experimental groups were resuspended in DCM plus 10 ng/ml TGF-β3.
DCM consisted of high-glucose DMEM, 1% ITS+Premix (6.25 µg/mL insulin, 6.25
µg/mL transferrin, 6.25 µg/mL selenious acid, 1.25 mg/mL bovine serum albumin, and
5.35 µg/mL linoleic acid), 0.1 µM dexamethasone, 50 mg/mL ascorbate-2 phosphate, 1
mM sodium pyruvate, 40 µg/mL L-proline, 1% antibiotic-antimycotic solution (100
15

U/mL penicillin, 0.1 mg/mL streptomycin, and 0.25 µg/mL amphotericin B). Each cell
suspension was evenly divided among 36 15-mL conical polypropylene centrifuge tubes
so that each tube contained approximately 4×105 cells in 0.75 ml of medium. Tubes were
centrifuged at 500g for 3 min and the resulting pellet cultures maintained in culture at 37
°C in a humidified atmosphere containing 95% air and 5% CO2. Figure 2.1 displays the
gross morphology of a pellet culture in phosphate buffered saline (PBS) at the final day
of the experiment.

Figure 2.1 Gross morphology of pellet culture in PBS.

The medium was replaced every 3-4 days for 21 days. After 3 days of culture in
DCM with TGF-β3, all media in the (TGF-β3→BMP-13) group was completely replaced
16

with DCM plus 10 ng/ml BMP-13, in which the cells were cultured for remainder of the
experiment. Chondroinduction was evaluated based on gene expression, histology, and
immunohistochemistry of pellets following 3, 10, and 21 days of culture. The medium
content for each group over the course of the experiment is displayed in Table 2.1.

Table 2.1 Groups defined according to medium content at each experimental time point.
Group Name

Day 0 - Day 3

Day 3 - Day 21

Group I

Expansion Medium

Expansion Medium

Group II

DCM + TGF-β3

DCM + TGF-β3

Group III

DCM + BMP-13

DCM + BMP-13

Group IV

DCM + TGF-β3

DCM + BMP-13

Histological and Immunocytochemical Analysis
In order to evaluate the chondrogenic differentiation of the pellets, samples grown
at three time points were extracted and immediately fixed in 10% buffered formalin. The
pellets were then infiltrated and embedded in paraffin and sectioned to slides (University
of Alabama-Birmingham’s Center for Metabolic Bone Disease). Sections were stained
with Hemotoxylin and Eosin (H&E) to evaluate the internal structure or Toluidine Blue
to evaluate proteoglycan concentration.
Additional sections were immunostained for detection of collagen types II and X.
Primary antibodies for immunohistochemistry were rabbit anti-human Collagen Type II
17

polyclonal antibody from MD Bioproducts (St. Paul, MN) and mouse anti-pig Collagen
X monoclonal antibody from Abcam (Cambridge, MA). Pellet sections for
immunohistochemistry were deparaffinized and rehydrated in xylene and graded ethanol,
respectively. GAG removal and collagen exposure were performed by incubating slides
in hyaluronidase (2 mg/ml in tris buffered saline) for 25 minutes at 95°C. Antigen
retrieval was then performed by incubating slides in pronase (0.5mg/ml in PBS) for 10
minutes at 95°C. Subsequent incubations were all at room temperature, beginning with
the primary antibody for one hour. Primary antibody diluted 1:10 in PBS with 1% bovine
serum albumin was applied to sections and allowed to infiltrate for one hour at room
temperature. Following the primary antibody, slides were stained following instructions
from the SuperPicture 3rd Gen IHC Detection Kit (Invitrogen Corp., Frederick, MD).
Multiple washes with PBS were performed between all incubations. Type II collagen and
type X collagen positively stain dark orange to brown in color. High-resolution images
were taken with the Leica DM 2500 microscope (Leica Microsystems Inc., Bannockburn,
IL) in transmitted light mode under the same exposure for all slides.

Glycosaminoglycan and DNA Measurement
Three pellets from each group at every time point were digested in 1% papain and
50 mM sodium acetate at 60°C overnight. The total DNA content of the digestate was
measured using the Hoechst method. Aliquots of the digestate were added to 0.1 μg/ml
bisBenzimide solution in Fluorescent Assay Buffer, and fluorescence intensity was
measured using a GloMax®-Multi Jr Single Tube Multimode Reader (Promega,
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Corporation, Madison, WI). DNA content was obtained from a standard curve prepared
with calf thymus DNA.
Total GAG content from the same papain digestate used in DNA analysis was
quantified using the Blyscan Glycosaminoglycan Assay kit (Biocolor, Newtonabby,
Northern Ireland), based on dimethyl methylene blue dye binding. The absorbance at 656
nm was measured with a BioTek μQuant Microplate Spectrophotometer (BioTek
Instruments, Winooski, VT), and GAG concentration was calculated using a standard
curve established from a chondroitin sulfate standard.

RNA Preparation and RT-PCR
Total RNA was prepared from undifferentiated MSCs (5 independent samples)
and from pellets (3 per experimental group) cultured for 3, 10, and 21 days. The
expression of selected genes was determined by TaqMan® qRT-PCR using pre-designed
and validated probe/primer sets (Asuragen Inc., Austin, TX). Genes of interest were
aggrecan, cartilage oligomeric matrix protein (COMP), and collagen types I, II, and X.
Total RNA (200ng) was reverse transcribed in a total reaction volume of 20 µL.
Assuming 100% cDNA synthesis efficiency, 10ng total RNA equivalent cDNA was
added to the master mix for a final volume of 15 µL in each PCR well. All amplifications
were performed in triplicate on a validated Applied Biosystems 7900HT real-time
thermocycler. PCR was initialized by incubation at 95°C for 10 m, followed by 40 cycles
of amplification: 95°C for 15 s, then 60°C for 1 m. Beta-2-microglobulin was used as a
normalizer gene for ΔCT calculations and the undifferentiated MSCs used as a calibrator
for calculation of fold changes by the ΔΔCT method.
19

Results of the RT-PCR data were represented as CT values. CT can be defined as
the threshold cycle number for PCRs at which an amplified product was first detected
[48]. The average CT was calculated for the normalizer gene, beta-2-microglobulin, and
treatment group samples, and ΔCT was determined as (the mean of the triplicate CT
values for the normalizer gene) minus (the mean of the triplicate CT values for treatment
group samples). ΔΔCT can be calculated by taking the difference between ΔCT of
treatment group sample and ΔCT of undifferentiated MSCs from Day 0. Fold change can
be described as a differential expression in the normalizer gene of a treatment group
sample compared to the Day 0 undifferentiated MSCs counterpart and calculated by 2ΔΔCT

[48].

Follow-Up Experiments
Based on results of the primary experiment described above, two follow-up
experiments were performed to further clarify the effectiveness of BMP-13 for sustaining
chondroinduction of primary human MSCs through the use of RT-PCR analysis. The first
follow-up experiment was designed to determine whether BMP-13 was responsible for
any of the elevation in chondrocyte gene markers after 3 days of chondroinduction by
TGF-β3. The initial gene expression experiment was repeated using cells from a 24 yearold male donor, but the only two experimental groups were (TGF-β3→BMP-13) and a
new group, (TGF-β3→DCM). At the same time the TGF-β3-containing medium was
replaced with the BMP-13-containing medium in the former group, DCM without any
growth factor replaced the medium and growth factor in the latter group. The second
follow-up experiment was designed to investigate the potential for BMP-13 to mitigate
20

the TGF-β3-induced upregulation of type X collagen RNA. The initial gene expression
experiment was repeated using cells from a 22-year old male donor. Again, only two
experimental groups were included, TGF-β3 and a new group, (TGF-β3→Combination),
in which 10 ng/ml BMP-13 was added to the TGF-β3 containing medium after Day 3.

Statistical Analysis
All data were analyzed by using SPSS for Windows software, version 12.0
(SPSS, Chicago, IL). Numerical results are expressed as the mean ± standard deviation.
A one-way analysis of variance and LSD posthoc test (α=0.05) were performed to test for
the interaction between treatment groups over time.
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CHAPTER III
RESULTS

Histological and Immunocytochemical Evaluation
H&E staining were done in order to analyze the cellular structure of the samples.
The stained sections for each group display a loss in cellular content over time. At each
progressive time point for all treatment groups following Day 3, cellular debris collected
in the center of the sphere of each of the pellet constructs. However, the perimeter of each
spherical section indicates live cellular content from the appearance of cell nuclei and
fibrous-like material. Figure 3.1 displays sections stained for H&E for each group at each
time point.

22

Figure 3.1 20X Histological sections of Groups stained with H&E.

23

Histological evaluation shows an intense staining with toluidine blue in all
treatment groups across time, indicating an ECM rich in proteoglycans. Following the
initial time point, a higher intensity of toluidine blue can be seen in the groups at both
Day 10 and Day 21 compared to that of Day 3. Groups do not seem to show a distinct
staining compared to one another. However, groups do show a higher staining intensity
from Day 3 to Day 10. Figure 3.2 displays sections stained for toluidine blue for each
group at each time point.
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Figure 3.2 40X Histological sections of Groups stained with Toluidine Blue.
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Immunocytochemical analysis of type II collagen shows a distinct staining in
Group II and Group IV at different time points, indicating the presence of type II
collagen. Group I at Day 3 stains relatively light for type II collagen, and no change is
exhibited over the remaining time points. Group II type II collagen staining at Day 3
displays a positive staining for type II collagen, and such fibers can be seen. Group II
displays no change in intensity of type II collagen staining over time. Group III at Day 3
stains very light in color, indicating little or no existence of type II collagen. Group III
remains light in staining over the course of the experimental time points. Group IV at
Day 3 displays a positive staining for type II collagen, and such fibers can be seen. At
Day 10, there is a dramatic decrease in type II collagen staining intensity for Group IV.
From Day 10 to Day 21, there is no relative change in type II collagen staining intensity
for Group IV. Figure 3.3 displays sections immunostained for type II collagen for all
groups at each time point.
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Figure 3.3 40X Histological sections of Groups immunostained for type II collagen.
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Immunocytochemical analysis of type X collagen shows a distinct staining in
Group II and Group IV at different time points, indicating the presence of type X
collagen. Group I at Day 3 shows a light stain indicating no existence of type X collagen.
Over time, the staining intensity for Group I remain unchanged with no type X collagen
present over the course of the experiment. Group II displays an intense type X collagen
stain at Day 3, indicating the presence of type X collagen. At Day 10, Group II type X
collagen stain appears more intense. From Day 10 and Day 21, the existence of type X
collagen is even more prevalent in the dark staining color and fibers. Group III at Day 3
shows a light stain indicating the little or no presence of type X collagen. Group III type
X collagen staining intensity remains unchanged with no presence of type X collagen
over time. Group IV displays an intense type X collagen stain at Day 3, indicating the
presence of the fiber. However, at Day 10, there is a dramatic decrease in type X staining
intensity, indicating a major loss in the fiber expression between time points. At Day 21,
type X collagen staining remains light in color similar to that of the previous time point
for Group IV. Figure 3.4 displays sections immunostained for type X collagen for each
group at each time point.
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Figure 3.4 40X Histological sections of Groups immunostained for type X collagen.
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Biochemical Analysis
Total GAG content (normalized to DNA) for the treatment groups at each time
point is displayed in Figure 3.5. GAG content for Group I at Day 3 averages a
(2.35±0.93) mean across six pellets. At Day 10, Group I undergoes a significant increase
in mean GAG content at (4.21±1.15) across pellets. Between Day 10 and Day 21, Group
I exhibits no significant change in GAG content averaging a mean of (2.96±1.10) across
pellets. GAG content for Group II at Day 3 averages a (1.31±0.24) mean across six
pellets. At Day 10, Group II undergoes a significant increase in mean GAG content at
(3.98±1.21) across pellets. Between Day 10 and Day 21, Group II exhibits no significant
change in mean GAG content averaging a mean of (3.42±0.93) across pellets. GAG
content for Group III at Day 3 averages a (1.85±0.62) mean across six pellets. At Day 10,
Group III undergoes a significant increase in mean GAG content at (4.36±1.17) across
pellets. Between Day 10 and Day 21, Group III exhibits no significant change in mean
GAG content averaging a mean of (2.58±0.64) across pellets. GAG content for Group IV
at Day 3 averages a (1.42±0.22) mean across five pellets. At Day 10, Group IV
undergoes a significant increase in mean GAG content at (3.93±0.92) across pellets.
Between Day 10 and Day 21, Group IV exhibits no significant change in mean GAG
content averaging a mean of (3.49±1.01) across pellets.
At Day 3, Group I demonstrated a significantly higher mean GAG content
compared to that of Group II and Group IV. Group III was not considered significantly
different from any of the other groups. GAG content for all groups did not significantly
differ at Day 10. However, GAG content on Day 10 was significantly higher than on Day
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3 by 135% (4.12±1.06 vs. 1.75±0.69 μg/μg, n = 6 per group). From Day 10 to Day 21,
groups again exhibited no significant difference when compared to one another.

Figure 3.5 Total GAG content averaged across pellets for each Group over time.

DNA content for Group I at Day 3 averages a (737.22±38.95) mean across six
pellets. At Day 10, Group I undergoes a significant decrease in mean DNA content at
(453.37±32.35) across pellets. Between Day 10 and Day 21, Group I exhibits no
significant change in DNA averaging a mean of (431.32±39.32) across pellets. DNA
content for Group II at Day 3 averages a (739.85±36.90) mean across six pellets. At Day
10, Group II undergoes a significant decrease in mean DNA content at (354.42±58.89)
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across pellets. Between Day 10 and Day 21, Group II exhibits no significant change in
DNA averaging a mean of (305.06±17.33) across pellets. DNA content for Group III at
Day 3 averages a (785.27±100.25) mean across six pellets. At Day 10, Group III
undergoes a significant decrease in mean DNA content at (438.17±19.01) across pellets.
Between Day 10 and Day 21, Group III exhibits no significant change in DNA averaging
a mean of (375.44±21.28) across pellets. DNA content for Group IV at Day 3 averages a
(808.01±29.99) mean across five pellets. At Day 10, Group IV undergoes a significant
decrease in mean DNA content at (341.50±53.31) across pellets. Between Day 10 and
Day 21, Group IV exhibits no significant change in DNA averaging a mean of
(307.97±29.88) across pellets.
At Day 3, treatment groups exhibited no significant difference between one
another. DNA content for Group I and Group III displayed significantly higher mean
values than that of Group II and Group IV at Day 10. From Day 10 to Day 21, Group I
and Group III again expressed a higher mean DNA content than that of groups Group II
and Group IV. However, Group I exhibited a significantly higher mean DNA content
than that of all groups. On Day 10 and Day 21, pellets from all groups contained about
50% of the DNA at which they had contained on Day 3. Total DNA content for the
groups at each time point is displayed in Figure 3.6.
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Figure 3.6 Total DNA content averaged across pellets for each Group over time.

Following statistical analysis for each gene’s mean fold change, the significant
comparison between treatment groups over time could be determined. The data is
presented as the fold change in target gene expressions for all treatment groups and is
relative to five independent samples of undifferentiated MSCs from Day 0.
Aggrecan expression for Group I at Day 3 averages a (-11.99±1.24) mean fold
change across pellets. At Day 10, aggrecan expression for Group I experiences a
significant increase in mean fold change at (-7.61±2.43). Between Day 10 and Day 21,
aggrecan expression increases but does not experience a significant change at a (6.36±0.78) mean fold change for Group I. Aggrecan expression for Group II at Day 3
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averages a (-3.40±1.83) mean fold change across pellets. At Day 10, aggrecan expression
for Group II experiences an increase in mean fold change at (-1.34±0.42). Between Day
10 and Day 21, aggrecan expression significantly increases at a (2.86±0.72) mean fold
change for Group II. Aggrecan expression for Group III at Day 3 averages a (-4.12±1.59)
mean fold change across pellets. At Day 10, aggrecan expression for Group III
experiences a decrease in mean fold change at (-11.07±6.10). Between Day 10 and Day
21, aggrecan expression significantly increases at a (1.14±0.09) mean fold change for
Group III. Aggrecan expression for Group IV at Day 3 averages a (-3.12±1.35) mean fold
change across pellets. At Day 10, aggrecan expression for Group IV experiences a
significant decrease in mean fold change at (-7.05±2.06). Between Day 10 and Day 21,
aggrecan expression significantly increases at a (-2.78±1.06) mean fold change for Group
IV. Group I and Group II aggrecan expression significantly differ between Day 3 and
Day 21.
At Day 3, aggrecan expression is significantly lower for Group I compared to that
of the other treatment groups. Group II and Group III exhibit the only significant
difference in mean fold change relative to aggrecan expression at Day 10, with Group II
having a significantly higher mean fold change value. At Day 21, Group I aggrecan
expression experiences a significantly lower mean fold change compared to that of the
other treatment groups. Also, Group II has a significantly higher mean fold change than
all groups at Day 21. All treatment groups at Day 21 experience a significant difference
from all other treatment groups with respect to aggrecan expression of mean fold change.
Total aggrecan mean fold change for the groups at each time point is displayed in Figure
3.7.
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Figure 3.7 Total aggrecan mean fold change in pellets over time for initial experiment.

COMP expression for Group I at Day 3 averages a (1.14±0.21) mean fold change
across pellets. At Day 10, COMP expression for Group I experiences a decrease in mean
fold change at (-2.03±0.07). Between Day 10 and Day 21, COMP expression experiences
a significant increase at a (4.43±3.83) mean fold change for Group I. COMP expression
for Group II at Day 3 averages a (76.57±22.54) mean fold change across pellets. At Day
10, COMP expression for Group II experiences a significant increase in mean fold
change at (728.70±172.75). Between Day 10 and Day 21, COMP remains relatively
unchanged at a (675.89±231.69) mean fold change for Group II. COMP expression for
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Group III at Day 3 averages a (-0.19±1.49) mean fold change across pellets. At Day 10,
COMP expression for Group III experiences a decrease in mean fold change at (-1.33
±0.36). Between Day 10 and Day 21, COMP expression significantly increases at a mean
fold change (7.11 ±0.87) for Group III. COMP expression for Group IV at Day 3
averages a (117.54±15.24) mean fold change across pellets. At Day 10, COMP
expression for Group IV experiences a significant decrease in mean fold change at
(48.28±15.28). Between Day 10 and Day 21, COMP expression decreases at a
(22.62±13.37) mean fold change for Group IV. Only Group I COMP expression did not
significantly differ between Day 3 and Day 21.
At Day 3, COMP expression is significantly lower for Group I and Group II
compared to Group II and Group IV mean fold change. COMP expression for Group II
expresses a significantly higher mean fold change compared to the other groups at Day
10. Group II COMP expression, again at Day 21, experiences a significantly higher mean
fold change compared to the remaining groups. Total COMP mean fold change for the
groups at each time point is displayed in Figure 3.8.

36

Figure 3.8 Total COMP mean fold change in pellets over time for initial experiment.

Type I collagen expression for Group I at Day 3 averages a (-1.49±0.28) mean
fold change across pellets. At Day 10, type I collagen expression for Group I experiences
an increase in mean fold change at (-0.34±1.22). Between Day 10 and Day 21, type I
collagen expression experiences a significant increase at a (1.88±0.30) mean fold change
for Group I. Type I collagen expression for Group II at Day 3 averages a (2.84±0.28)
mean fold change across pellets. At Day 10, type I collagen expression for Group II
experiences a significant increase in mean fold change at (6.17±1.45). Between Day 10
and Day 21, type I collagen increases at a (8.27±1.24) mean fold change for Group II.
Type I collagen expression for Group III at Day 3 averages a (1.31±0.40) mean fold
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change across pellets. At Day 10, type I collagen expression for Group III experiences an
increase in mean fold change at (1.71±0.17). Between Day 10 and Day 21, type I
collagen expression significantly increases at a mean fold change (5.12±0.30) for Group
III. Type I collagen expression for Group IV at Day 3 averages a (2.56±0.45) mean fold
change across pellets. At Day 10, type I collagen expression for Group IV experiences an
increase in mean fold change at (3.57±0.24). Between Day 10 and Day 21, type I
collagen expression significantly increases at a (4.65±0.78) mean fold change for Group
IV. All groups type I collagen expression differ significantly between Day 3 and Day 21.
At Day 3, type I collagen expression is significantly lower for Group I compared
to the remaining groups. Group II and Group IV also exhibit a significantly higher mean
fold change than Group III in type I collagen expression at Day 3. Again, Group I type I
collagen expression exhibits a significantly lower mean fold change, and Group II
exhibits a significantly higher mean fold change compared to remaining groups at Day
10. Group IV also expresses a significantly higher type I collagen expression than Group
III. Group II, Group III and Group IV type I collagen expression, at Day 21, experiences
a significantly higher mean fold change compared to that of the remaining group, Group
I. However, Group II has a significantly higher mean fold change type I collagen
expression than all groups at Day 21. Total type I collagen mean fold change for the
groups at each time point is displayed in Figure 3.9.
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Figure 3.9 Total type I collagen mean fold change in pellets over time for initial
experiment.
At Day 10, type II collagen expression for Group I experiences a mean fold
change at (2.15±0.55). Between Day 10 and Day 21, type II collagen expression
experiences an increase at a (2.72±1.36) mean fold change for Group I. Type II collagen
expression for Group II at Day 3 averages a (11.87±8.72) mean fold change across
pellets. At Day 10, type II collagen expression for Group II experiences an insignificant
decrease in mean fold change at (9.33±7.97). Between Day 10 and Day 21, type II
collagen remains relatively unchanged at (8.95±4.03) mean fold change for Group II. The
type II collagen expression for Group III at Day 3 averages a (0.37±1.42) mean fold
change across all pellets. At Day 10, type II collagen expression for Group III
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experiences an increase in mean fold change at (2.24±0.99). Between Day 10 and Day
21, type II collagen expression decreases at a mean fold change (0.46±1.76) for Group
III. The type II collagen expression for Group IV at Day 3 averages a (14.67±4.57) mean
fold change across all pellets. At Day 10, type II collagen expression for Group IV
experiences a significant decrease in mean fold change at (4.83±1.73). Between Day 10
and Day 21, type II collagen expression decreases at a (2.76±0.604) mean fold change for
Group IV. Group IV type II collagen expression differs significantly between Day 3 and
Day 21. Also, all treatment groups exhibit no significant change in type II collagen
content from Day 10 to Day 21.
At Day 3, type II collagen expression is significantly lower for Group III
compared to the remaining groups present. Type II collagen expression does not exhibit a
significantly different mean fold change among all groups at Day 10. Group II type II
collagen expression experiences a significantly higher mean fold change compared to that
of the remaining groups at Day 21. Total type II collagen mean fold change for the
groups at each time point is displayed in Figure 3.10.
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Figure 3.10 Total type II collagen mean fold change in pellets over time for initial
experiment.
Type X collagen expression for Group I at Day 3 averages a (-3.53±0.79) mean
fold change across pellets. At Day 10, type X collagen expression for Group I
experiences a significant decrease in mean fold change at (-12.20±2.45). Between Day 10
and Day 21, type X collagen expression experiences a significant increase at a
(0.56±3.93) mean fold change for Group I. Type X collagen expression for Group II at
Day 3 averages a (449.57±70.27) mean fold change across pellets. At Day 10, type X
collagen expression for Group II experiences an increase in mean fold change at
(547.52±17.84). Between Day 10 and Day 21, type X collagen significantly increases at a
(875.31±177.72) mean fold change for Group II. Type X collagen expression for Group
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III at Day 3 averages a (3.41 ±1.59) mean fold change across pellets. At Day 10, type X
collagen expression for Group III remains relatively unchanged in mean fold change at
(5.77±3.15). Between Day 10 and Day 21, type X collagen expression significantly
increases at a mean fold change (44.45±12.71) for Group III. Type X collagen expression
for Group IV at Day 3 averages a (361.23±78.19) mean fold change across pellets. At
Day 10, type X collagen expression for Group IV experiences a significant decrease in
mean fold change at (20.86±3.56). Between Day 10 and Day 21, type X collagen
expression remains relatively unchanged at a (44.63±27.65) mean fold change for Group
IV. Group II, Group III, and Group IV type X collagen expression differ significantly
between Day 3 and Day 21.
At Day 3, type X collagen expression is significantly higher for Group II and
Group IV compared to that of Group I and Group III. Type X collagen expression for
Group II expresses a significantly higher mean fold change compared to the other groups
at Day 10. Again, Group II type X collagen expression experiences a significantly higher
mean fold change compared to that of the remaining groups at Day 21. Total type X
collagen mean fold change for the groups at each time point is displayed in Figure 3.11.
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Figure 3.11 Total type X collagen mean fold change in pellets over time for initial
experiment.
Follow-Up Experiments
RT-PCR Analysis
The first follow-up experiment was designed to determine whether BMP-13 was
responsible for any of the elevation in chondrocyte gene markers after 3 days of
chondroinduction by TGF-β3, with only two experimental groups present, (TGFβ3→BMP-13) and (TGF-β3→DCM). Total RNA was prepared from undifferentiated
MSCs and also from pellets cultured at days 3 and 10 using the Qiagen RNeasy mini kit.
RT-PCR analysis followed the same experimental outline as discussed previously. Group
(TGF-β3→BMP-13) exhibits a mean (-14.80±1.74) fold change at Day 3 aggrecan
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expression. At Day 10, (TGF-β3→BMP-13) undergoes a significant decrease in aggrecan
expression at a mean fold change of (-114.14±17.26). Group (TGF-β3→DCM) exhibits a
mean (-14.56±4.07) fold change at Day 3 aggrecan expression. At Day 10, (TGFβ3→DCM) undergoes a significant decrease in aggrecan expression at a mean fold
change of (-105.95±0.00). At Day 3 and Day 10, Group (TGF-β3→BMP-13) and Group
(TGF-β3→DCM) do not exhibit a significant difference in aggrecan expression. Total
aggrecan mean fold change for the groups at each time point for the first follow-up
experiment is displayed in Figure 3.12.

Figure 3.12 Total aggrecan mean fold change in pellets over time for first follow-up
experiment.
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Group (TGF-β3→BMP-13) exhibits a mean (-4.44±0.37) fold change at Day 3
COMP expression. At Day 10, (TGF-β3→BMP-13) undergoes a significant decrease in
COMP expression at a mean fold change of (-43.28±3.62). Group (TGF-β3→DCM)
exhibits a mean (-4.81±0.71) fold change at Day 3 COMP expression. At Day 10, (TGFβ3→DCM) undergoes a significant decrease in COMP expression at a mean fold change
of (-37.55±9.55). At Day 3 and Day 10, Group (TGF-β3→BMP-13) and Group (TGFβ3→DCM) do not exhibit a significant difference in COMP expression. Total COMP
mean fold change for the groups at each time point for the first follow-up experiment is
displayed in Figure 3.13.
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Figure 3.13 Total COMP mean fold change in pellets over time for first follow-up
experiment.
Group (TGF-β3→BMP-13) exhibits a mean (0.24±1.51) fold change at Day 3
type II collagen expression. At Day 10, (TGF-β3→BMP-13) remains relatively
unchanged in type II collagen expression at a mean fold change of (1.11±2.21). Group
(TGF-β3→DCM) exhibits a mean (-2.29±0.82) fold change at Day 3 type II collagen
expression. At Day 10, (TGF-β3→DCM) remains relatively unchanged in type II
collagen expression at a mean fold change of (-0.40±1.31). At Day 3 and Day 10, Group
(TGF-β3→BMP-13) and Group (TGF-β3→DCM) do not exhibit a significant difference
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in type II collagen expression. Total type II collagen mean fold change for the groups at
each time point for the first follow-up experiment is displayed in Figure 3.14.

Figure 3.14 Total type II collagen mean fold change in pellets over time for first followup experiment.
Group (TGF-β3→BMP-13) exhibits a mean (377.85±76.63) fold change at Day 3
type X collagen expression. At Day 10, (TGF-β3→BMP-13) undergoes a significant
decrease in type X collagen expression at a mean fold change of (4.21±0.52). Group
(TGF-β3→DCM) exhibits a mean (441.715±19.58) fold change at Day 3 type X collagen
expression. At Day 10, (TGF-β3→DCM) undergoes a significant decrease in type X
collagen expression at a mean fold change of (3.74±0.38). At Day 3 and Day 10, Group
(TGF-β3→BMP-13) and Group (TGF-β3→DCM) do not exhibit a significant difference
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in type X collagen expression. Total type X collagen mean fold change for the groups at
each time point for the first follow-up experiment is displayed in Figure 3.15.

Figure 3.15 Total type X collagen mean fold change in pellets over time for first followup experiment.
The second follow-up experiment was designed to investigate the potential for
BMP-13 to mitigate the TGF-β3-induced upregulation of type X collagen expression.
The experimental groups were TGF-β3 and a new group, (TGF-β3→Combination), in
which 10 ng/ml BMP-13 was added to the TGF-β3 containing medium after Day 3. Total
RNA was prepared from undifferentiated MSCs and also from pellets cultured at day 10
using the Qiagen RNeasy mini kit. RT-PCR analysis followed the same experimental
outline as discussed previously.
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Group TGF-β3 exhibits a mean (18.76±3.38) fold change at Day 10 type X
collagen expression. Group (TGF-β3→Combination) exhibits a mean (21.66±0.00) fold
change at Day 10 type X collagen expression. By Day 10, Group TGF-β3 and Group
(TGF-β3→Combination) do not exhibit a significant difference in type X collagen
expression. Total type X collagen mean fold change for the groups at each time point for
the second follow-up experiment is displayed in Figure 3.16.

Figure 3.16 Total type X collagen mean fold change in pellets over time for second
follow-up experiment.
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CHAPTER IV
DISCUSSION

In this study, the concentration and time interval of growth factors, TGF- β3 and
BMP-13, are manipulated in order to determine their effect on chondrogenic
differentiation of bone marrow-derived MSCs. The hypothesis, that human bone marrowderived MSCs can be driven to differentiate toward a chondrogenic lineage after the
application of BMP-13, was tested by the analyses presented. The results indicate that the
application of BMP-13 alone does not exert a strong chondroinductive effect on MSCs.
However, the data does suggest that BMP-13 has the ability to sustain chondroinduction
to a certain extent for up to 18 days following initiation by 3 days of exposure to TGF-β3.
The total GAG content was found to be significantly higher for Group I compared
to that of Group II and Group IV at the first experimental time point. Group III was not
considered significantly different from any of the other treatment groups at Day 3.
Following the initial time point, GAG content for all treatment groups was significantly
higher than on Day 3 by 135%, and all groups did not significantly differ with regards to
GAG content. The significant increase in GAG content suggests that all Groups promote
differentiation of MSCs from Day 3 to Day 10. From Day 10 to Day 21, GAG content
was not significantly different for all treatment groups between time points, and treatment
groups again exhibited no significant difference in GAG content when compared to one
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another. Previous studies have reported an initial increase, and the leveling off of GAG
content in cartilage tissue engineering [49]. This leveling of GAG content could be
associated with a higher turnover per cell accompanying the decrease in DNA content
presented across groups [30]. Previous studies, comparing seeding cell density, have
reported that a higher initial cell-density has been proven to produce more proteoglycan
in the presence of TGF- β3 [50, 51].
The total DNA content was found to be similar among the treatment groups at the
first experimental time point. Following the initial time point, there is a significant
decrease in DNA content in all treatment groups, suggesting cellular death. Group I and
Group III had significantly higher DNA content at Day 10 and Day 21 compared to that
of Group II and Group IV. Group I also had a significantly higher DNA content than
Group III at Day 21. All treatment groups containing growth factors, Group II, Group III,
and Group IV, had a significantly lower DNA content compared to pellets cultured in
expansion medium, Group I. Groups do not demonstrate a significant change in DNA
content from Day 10 to Day 21, indicating the maintenance of cell density. The results
suggest that MSCs were lost at the initiation of chondroinduction. The sections stained
with H&E also indicate the loss of cells, which is indicated by the collection of cellular
debris in the center of all pellets over time. The loss of MSCs in pellet culture with
additional growth factors has been reported by previous studies [52, 53]. These studies
also reported loss of DNA content in pellets induced by TGF-β and BMP growth factors,
suggesting little cell proliferation or apoptosis throughout the course of differentiation.
Aggrecan fold change was found to be significantly higher for Group II, Group
III, and Group IV compared to that of Group I at the first experimental time point.
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Aggrecan expression for all treatment groups express a negative fold change value,
indicating little presence or absence of the aggrecan protein at Day 3. Following the
initial time point, Group II expresses a significantly higher mean fold change compared
to that of Group III at Day 10. After the removal of growth factor TGF-β3 and the
addition of growth factor BMP-13, Group IV experiences a significant decrease in mean
fold change in aggrecan gene expression from Day 3 to Day 10. At Day 10, all treatment
groups again express a negative aggrecan mean fold change. Treatment groups at Day 21
all exhibit a significant difference from one another. Group II expresses a significantly
higher mean fold change and Group I a significantly lower mean fold change. Group II
and Group III both exhibit positive mean fold change aggrecan expression by Day 21.
Aggrecan message was not detected in the MSCs of Group I by RT-PCR, but appeared
after treatment with TGF-β3 and BMP-13 after 21 days. The results suggest that growth
factor BMP-13, similar to that of TGF-β3, originally do not encourage the expression of
aggrecan, but slowly seem to support the presence of aggrecan with a positive mean fold
change by Day 21. The initial absence of aggrecan expression for groups may be an
effect of pelleting at the initiation of the experiment. Previous studies have also reported
that growth factor BMP-13 induced upregulation of the mature chondrocyte marker,
aggrecan [37].
COMP mean fold change was found to be significantly higher for Group II and
Group IV compared to that of the remaining groups at the initial experimental time point.
Following Day 3, Group II continues to express a significantly higher mean fold change
compared to the remaining treatment groups at both Day 10 and Day 21. Group II is the
only treatment group that is able to initiate, sustain and increase COMP gene expression
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throughout the experiment. Group IV initiates the production of COMP at Day 3, but
following the removal of TGF-β3 and addition of BMP-13 COMP mean fold change
significantly decreases. COMP message was not detected in the MSCs of Group I by RTPCR and appeared after treatment with TGF-β3. The results and previous studies indicate
the ability of TGF- β3 to initiate COMP expression, and the limited ability BMP-13 to
initiate or sustain the expression of the protein [30].
Type I collagen expression for Group II and Group IV exhibit a significantly
higher mean fold change compared to the remaining groups at the initial experimental
time point. Following Day 3, Group II continues to exhibit the highest significant mean
fold change among treatment groups at Day 10 and Day 21. Group II, Group III, and
Group IV have significantly higher mean fold change type I collagen expression
compared to that of the MSCs of Group I at Day 21. Following the removal of TGF-β3
and the addition of BMP-13 to DCM in Group IV at Day 3, type I collagen expression
remains relatively unchanged. The results suggest that BMP-13 may be capable of
sustaining the type I collagen expression initiated by TGF-β3. Type I collagen is detected
under the influence of both growth factors.
In terms of chondrogenic differentiation, type I collagen is not desirable. Growth
factor BMP-13 demonstrates a significantly lower expression of type I collagen,
compared to that of the growth factor TGF- β3. Barry et al. also report the type I collagen
uniform expression throughout differentiation in the presence of TGF- β3. Collagen type
I gene was expressed in the TGF- β3 and BMP-13 treated pellets. These results suggest
that the MSCs may not have completely differentiated into chondrocyte-like cells after a
21-day treatment of growth factors, and has also reported seen in previous studies [50].
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Nochi et al. also reported no suppression of type I collagen by the growth factor BMP-13,
although the osteogenic phenotype associated with type I collagen had been diminished
through the use of another member of the bone morphogenic protein family, BMP-2.
Type I collagen message showed a gradual increase in the untreated MSCs of
Group I, and was readily detected after 21 days in pellet culture. The presence of type I
collagen in the control group, Group I, at Day 21 suggests the osteogenic potential of
human bone marrow-derived MSCs, which has been suggested in previous studies in
regards to the C3H10T1/2 cell line [37].
Type II collagen expression is significantly higher for Group II and Group IV
compared to that of Group III at the initial experimental time point. Following Day 3, all
treatment groups express no significant difference in mean fold change for type II
collagen expression. However, Group IV undergoes a significant decrease in mean fold
change in type II collagen expression, following the removal of growth factor TGF-β3
and addition of growth factor BMP-13 to the DCM. At Day 21, Group II shows a
significantly higher type II collagen expression compared to that of the remaining
treatment group, suggesting that TGF- β3 may have the ability to increase type II
collagen expression more than that of BMP-13. Type II collagen expression remains
relatively unchanged for Group I, Group II and Group III over the course of the
experiment. Type II collagen message was uniformly detected in the MSCs of Group I
and throughout differentiation in pellet culture. Previous studies indicate a gradual
increase over time in type II collagen under the influence of TGF- β3 [30], and an
upregulation in type II collagen of MSCs stimulated by BMP-13 [37, 54]. However, this
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could be a reflection of the differentiation state of cells under study, rather than the
signals being transduced by the BMP-13 growth factor.
Type X collagen expression is significantly higher for Group II and Group IV
compared to that of Group I and Group III at the initial experimental time point. At Day
10, Type X collagen expression for Group II expresses a significantly higher mean fold
change compared to the remaining treatment groups. Group IV experiences a significant
decrease in type X collagen expression from Day 3 to Day 10. Group II type X collagen
expression experiences a significantly higher mean fold change compared to that of the
remaining treatment groups at Day 21. As expected, Group II, under the influence of
TGF-β3, experiences a significantly higher mean fold change compared to that of all
treatment groups, and undergoes significant increases in type X collagen over time.
Previous reports also have stated that in the presence of TGF-β3, MSCs display an upregulation of type X collagen over time [30, 55]. However, Group IV undergoes a
significant decrease in type X collagen expression following the removal of growth factor
TGF- β3 and addition of growth factor BMP-13 to DCM. The results suggest that BMP13 does not promote the expression of type X collagen.
Following initial experiments, the question still remained whether BMP-13 was
responsible for suppressing the expression of certain genes, or if it was the removal of
TGF-β3 that lead to the decrease in gene expression. Group IV undergoes a significant
decrease in gene expression for aggrecan, COMP, type II collagen, and type X collagen
at Day 10, following the removal of TGF-β3 and the addition of BMP-13. Follow-up
experiments were conducted in order to further determine the influence of BMP-13 on
MSCs.
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The first follow-up experiment was designed to determine whether BMP-13 was
responsible for any elevation in chondrocyte gene markers after 3 days of
chondroinduction by TGF-β3. The results suggest the limited ability of BMP-13 to
induce chondroinduction of MSCs. The aggrecan expression for Group (TGF-β3→BMP13) and Group (TGF-β3→DCM) undergoes a significant decrease following the removal
of TGF- β3 at Day 3. Group (TGF-β3→BMP-13) and Group (TGF-β3→DCM) exhibit
no significant difference in aggrecan expression from one another at Day 10. The results
suggest that the removal of TGF-β3 is responsible for a significant decrease in mean fold
change of aggrecan expression. BMP-13 is not responsible for the suppression of the
aggrecan gene, but may experience an initial decrease in mean fold change like that seen
in the initial experiment, to be followed by a significant increase in aggrecan mean fold
change.
The COMP expression for Group (TGF-β3→BMP-13) and Group (TGFβ3→DCM) undergoes a significant decrease following the removal of TGF- β3 at Day 3.
Group (TGF-β3→BMP-13) and Group (TGF-β3→DCM) exhibit no significant
difference in COMP expression from one another at Day 10. The results suggest that the
removal of TGF-β3 is responsible for a significant decrease in COMP expression. BMP13 is not responsible for the suppression of the COMP gene.
Type II collagen expression for Group (TGF-β3→BMP-13) and Group (TGFβ3→DCM) remains relatively unchanged following the removal of TGF- β3 at Day 3.
Group (TGF-β3→BMP-13) and Group (TGF-β3→DCM) exhibit no significant
difference in type II collagen expression from one another at Day 10. The results suggest
that the initial presence of TGF- β3 is responsible for the expression of type II collagen.
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BMP-13 does not seem to play a vital role in the up-regulation or sustainability in the
expression of type II collagen.
Type X collagen expression for Group (TGF-β3→BMP-13) and Group (TGFβ3→DCM) undergoes a significant decrease following the removal of TGF- β3 at Day 3.
Group (TGF-β3→BMP-13) and Group (TGF-β3→DCM) exhibit no significant
difference in type X collagen expression from one another at Day 10. The results suggest
that the removal of TGF-β3 is responsible for a significant decrease in type X collagen
expression. BMP-13 is not responsible for the suppression of the type X collagen gene.
The second follow-up experiment was designed to better understand the affect of
BMP-13 on the alleviation of type X collagen in TGF- β3 induced MSCs. The results
suggest the limited ability of BMP-13 to repress type X collagen following initiation with
TGF-β3. Type X collagen expression for Group (TGF-β3) and Group (TGFβ3→Combination) exhibit no significant difference relative to type X collagen expression
at Day 10. From the initial experiment, we recognize that TGF-β3 is responsible for a
significant increase in type X collagen expression. BMP-13, when added in combination
with TGF-β3, exhibits no capabilities of suppressing type X collagen expression.
In summary, this study has demonstrated that chondrogenesis of human bone
marrow-derived MSCs can be sustained with the treatment of BMP-13 as attested by the
results of gene expression analyses and histological and immunohistochemical
assessments. BMP-13 appears to have some limited capacity for chondroinduction, much
less than that of pellet cultures stimulated by TGF-β3. However, the chondroinduction
stimulated by BMP-13 is not accompanied by an increase in type I collagen and type X
collagen expression as demonstrated with TGF-β3.
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In this study, we proved that BMP-13 is capable of stimulating proliferation and
the aggregation of undifferentiated MSCs. BMP-13 is able to sustain type II collagen
expression following initiation with TGF-β3, but alone does not have the capability to
express the protein considered to be the basis of articular cartilage. BMP-13 does not
exert a strong influence on the expression of chondrogenic specific markers, aggrecan,
COMP, and type II collagen, but BMP-13 does not act to suppress the expression of these
genetic markers. Initial experiments prematurely suggested that BMP-13 might be
responsible for the suppression the expression of aggrecan, COMP, type II collagen and
type X collagen. However, follow-up experiments reported that the removal of TGF-β3
was responsible for the significant decrease in gene expression. In order to improve this
method of tissue engineering, future studies should be conducted to establish the model
growth factor and MSC conditions required to simulate the properties consistent with
articular cartilage.
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